Acurx Pharmaceuticals, Inc.
ACXP· Nasdaq
ACXPAcurx Pharmaceuticals, Inc.
Filed Aug 13, 2026 · 10-Q · 44 days after period end · 0001104659-26-095904
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$2.25M | -$2.25M | -$4.12M | -$3.45M |
| EPS Diluted | -$0.53 | -$1.89 | -$5.21 | -$0.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acurx Pharmaceuticals, Inc. · CIK 1736243 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end
